[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"methamphetamine-intoxication\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:methamphetamine-intoxication":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100571533",false,"NCT06721494","A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of Methamphetamine","A Phase 2 Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants With Methamphetamine Use Disorder Not Seeking Treatment Receiving a Single Dose of Methamphetamine","Major Inclusion Criteria:\n\n1. Healthy participants aged 18 to 55 years, inclusive;\n2. Meets DSM-5 criteria for methamphetamine use disorder;\n3. Not seeking treatment for methamphetamine use disorder;\n4. Primary route of methamphetamine self-administration must be intravenous or smoking;\n5. Able to abstain from methamphetamine without experiencing severe withdrawal;\n6. A body mass index between 18 to 30 kg\u002Fm2, inclusive and a minimum body weight of 50 kg;\n7. Females must not be lactating and must have a negative pregnancy test during screening and admission.\n\nMajor Exclusion Criteria:\n\n1. Estimated glomerular filtration rate \\\u003C60 mL\u002Fmin\u002F1.73 m2;\n2. History of cardiovascular disease;\n3. Current moderate to severe use disorder for alcohol, cannabis, cocaine, opioids, or benzodiazepines;\n4. History of any clinically important disease or disorder which, in the opinion of the Investigator, may interfere with safe study participation.","ALL","18 Years","55 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The purpose of the study is to evaluate the safety, efficacy, and pharmacokinetics of four single, increasing doses of CS-1103, given by intravenous (IV) infusion in otherwise healthy, non-treatment seeking participants with methamphetamine use disorder in the presence of a clinically relevant dose of methamphetamine HCl (30 mg IV).",[26,27,28],"Methamphetamine Intoxication","Methamphetamine Disorders","Methamphetamine Abuse","RECRUITING","2026-01-09",{"date":32,"type":33},"2026-01-12","ACTUAL",{"date":35,"type":20},"2026-02-05",{"date":37,"type":20},"2026-09-11",{"name":39,"class":40},"Clear Scientific, Inc.","INDUSTRY",""]